Australia has a real opportunity in healthcare AI. We will only take it if we stop behaving as passive buyers of overseas technology.
We have strong clinicians. Credible research institutions. A regulatory environment that takes safety seriously without being paralytic about it. A healthcare system complex enough to test real-world implementation, but small enough to build disciplined, exportable models without losing sight of the patient. That combination is rarer than we admit. Most countries have one of those things. Very few have all of them.
CTI's position has been the same since we started: Regenemm should be built as Australian healthcare infrastructure first, with global relevance to follow. Not the other way around.
The R&D programme reflects that order of operations. Our 2023-2024 R&D report describes a platform designed to combine physiological and psychometric inputs to analyse health and stress-performance, and to connect healthcare stakeholders so that data can be shared safely and acted on quickly. That isn't a single product. That is infrastructure thinking applied to healthcare.
The technical work behind it has not been trivial. Clinical audio processing in noisy environments. Multi-speaker diarisation. Hallucination reduction in clinical summarisation. Wearable-data integration. Biometric and audio synchronisation. Swift and SwiftUI development for the clinician-facing apps. Core ML direction for on-device inference. OCR. NLP expansion. Clinical databases. FHIR-based structure across all of it. None of that gets done in a weekend, and none of it gets done well by a team that doesn't take healthcare seriously.
That is exactly the kind of R&D Australian companies should be doing — not licensing in from somewhere else and translating the workflow afterwards.
The ISMS and Vanta work adds the other half of the picture, the half that doesn't make headlines but does decide whether a hospital trusts you. CTI's ISMS scope covers the assets, personnel and processes — at CTI and at Regenemm Healthcare — that store, process or transmit sensitive health, personal or confidential data. The included environments span AWS, Firebase and Firestore, Apple Silicon inference nodes, GitHub pipelines, the Terraform backend, Vanta itself, PagerDuty and the observability stack. Healthcare AI doesn't get judged only on cleverness. It gets judged on security, privacy, auditability, resilience, governance, interoperability, and whether the clinician's day actually gets easier rather than harder. Those judgments happen quietly, by procurement teams and CISOs, long before anyone sees a demo.
I do not believe the future of healthcare AI belongs to generic models dropped into clinical workflows from above. The future belongs to systems built close to the clinical reality — the ward, the operating theatre, the consulting room, the nursing handover, the discharge process, the GP letter, the patient explanation, and the EMR integration point where most of these projects quietly die. That is where the work is. That is where the trust gets built.
That is where CTI sits, and where we intend to keep sitting.
Australian healthcare AI should be evidence-seeking. It should respect consent in code, not just on paper. It should use FHIR properly. It should work with the EMRs hospitals already have, not pretend they don't exist. It should be clinically reviewed, risk-managed and auditable. It should be built and tested with the people who actually deliver care, not designed at them.
Most importantly, it should make care better.
That is the only metric that matters in the end. Everything else is just scaffolding.
CTI is the AI-native parent company behind Regenemm Healthcare.
